TY - T1的回应信给编辑J-00920-2021 JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01076-2021 SP - 2101076 AU - Izquierdo, Jose L. AU - Soriano, Joan B. Y1 - 2021/01/01 UR - //www.qdcxjkg.com/content/early/2021/07/01/13993003.01076-2021.abstract N2 - We take the opportunity to respond to Wark PAB, et al. [1]. on our recent publication [2]. it is indeed worth exploring the relationships of respìratory disease and SARS-CoV-2 infection COVID-19, and the potential mechanisms involved to understand better the pathophysiology of COVID-19, and eventually new treatments. However, based on others and our own observations, we disagree with the statement that use of Th2 targeting biologics in patients with asthma may increase susceptibility to SARS-CoV-2 infection due to an increased expression of ACE2. Our results in Table 3 with biologics (omalizumab n=641, mepolizumab n=308, benralizumab n=98, reslizumab n=26) point to a beneficial effect in asthmatics with COVID-19, as suggested elsewhere [3].Biologics may have a beneficial effect in asthmatics with COVID-19 ER -